Loading...
Market
Will Shift Bioscience's platform receive clinical trial approval by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Regulatory body announcements or Shift Bioscience press releases
Story
Shift Bioscience Raises $16M with Healthspan Capital to Advance AI-Driven Cell Rejuvenation Platform
Oct 15, 2024, 11:07 AM
British startup Shift Bioscience has successfully raised $16 million in seed funding to advance its AI-driven cell simulation platform. The funding will be used to identify genes that can safely rejuvenate aging cells by rewinding the epigenetic clock. This initiative aims to develop therapeutics for age-related diseases without the risks associated with Yamanaka factors. Shift Bioscience's platform leverages artificial intelligence to simulate cell behavior and identify potential gene-factors for rejuvenation. The investment was led by Healthspan Capital, marking a significant milestone for the company. Daniel / Shift Bio was the first company Healthspan Capital invested in.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant efficacy • 25%
Moderate efficacy • 25%
No efficacy • 25%
Inconclusive results • 25%